Solutions / Business

Most of the cardiovascular risk in a workforce never reaches a cardiologist.

Biospark studies continuous cardiovascular intelligence as field science for enterprise health: a watch on the high-risk chest, not an annual biometric event.

Employed populations still carry the country's leading cause of death. Between 2021 and 2023, 130.6 million U.S. adults (48.9%) had some form of cardiovascular disease (AHA 2026). Heart failure alone is 7.7 million adults. The Institute's operating observation is that only about 17% of heart-failure patients ever see a cardiologist. The rest are managed in primary care, if they are managed at all.

Annual screening finds a snapshot. Cardiothoracic Field Science is built for the interval: a multisensor chest recording (seismic cardiography, acceleration, acoustics, and ECG) read as a trajectory, so decompensation and missed titration are researchable events rather than surprises.

In 2026 clinical performance research, a 61-patient strip study compared the chest recording with a gold-standard 12-lead ECG (heart-rate RMSE 0.01 BPM; PR, QRS, and QT met the study's equivalence bars). A 52-subject long-term analysis against a Holter reference met a pre-set bar of greater than 75% sensitivity and greater than 75% PPV on reported arrhythmia endpoints. Those are device-performance studies, not workforce outcomes.

Field outcomes remain the dated Prevail Heart Clinics cohort (October 2014 through May 2016, n=394, care predominantly by a physician assistant): 6.1% all-cause 30-day readmission against a 24.7% contemporaneous Medicare CHF benchmark, and a 71.4% reduction in heart-failure hospitalizations in the first year. A larger outcomes refresh is underway.

The Institute does not sell a wellness wearable. It develops the science that lets an enterprise health program see the high-risk chest between visits.